DanCann Pharma A/S: Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
COPENHAGEN, Denmark, 26 April 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce an update on their U.S. REBORN1 Clinical Trial.DanCann Pharma signed February 25th a Letter of Intent (LOI) with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany. This press release is passed on from Tetra's own press release, concerning that Tetra has shipped the investigational new drug, QIXLEEF, to the USA